Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1291 to 1305 of 1505 results for patients and public

  1. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    In development Reference number: GID-TA11491 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]

    In development Reference number: GID-TA11588 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]

    In development Reference number: GID-TA11634 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    In development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]

    In development Reference number: GID-TA11888 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development Reference number: GID-TA11010 Expected publication date: TBC

    Technology appraisal guidance
    In development